Hypoxia-inducible factor1 (HIF-1) is an essential transcription factor for cellular adaptation to decreased oxygen availability. In normoxia the oxygen-sensitive α-subunit of HIF-1 is hydroxylated on Pro564 and Pro402 and thus targeted for proteasomal degradation. Three human oxygen-dependent HIF-1α prolyl hydroxylases (PHD1, PHD2, and PHD3) function as oxygen sensors in vivo. Furthermore, the asparagine hydroxylase FIH-1 (factor inhibiting HIF) has been found to hydroxylate Asp803 of the HIF-1 C-terminal transactivation domain, which results in the decreased ability of HIF-1 to bind to the transcriptional coactivator p300/CBP. We have fused these enzymes to the N-terminus of fluorescent proteins and transiently transfected the fusion proteins into human osteosarcoma cells (U2OS). Three-dimensional 2-photon confocal fluorescence microscopy showed that PHD1 was exclusively present in the nucleus, PHD2 and FIH-1 were mainly located in the cytoplasm and PHD3 was homogeneously distributed in cytoplasm and nucleus. Hypoxia did not influence the localisation of any enzyme under investigation. In contrast to FIH-1, each PHD inhibited nuclear HIF-1α accumulation in hypoxia. All hydroxylases suppressed activation of a cotransfected hypoxia-responsive luciferase reporter gene. Endogenous PHD2mRNA and PHD3mRNA were hypoxia-inducible, whereas expression of PHD1mRNA and FIH-1mRNA was oxygen independent. We propose that PHDs and FIH-1 form an oxygen sensor cascade of distinct subcellular localisation.

Studies on hypoxia-sensitive pathways have revealed a series of Fe(II)-dependent dioxygenases that regulate hypoxia-inducible factor (HIF) by prolyl and asparaginyl hydroxylation. The recognition of these unprecedented signaling processes has led to a search for other substrates of the HIF hydroxylases. Here we show that the human HIF asparaginyl hydroxylase, factor inhibiting HIF (FIH), also efficiently hydroxylates specific asparaginyl (Asn)-residues within proteins of the IB family. After the identification of a series of ankyrin repeat domain (ARD)-containing proteins in a screen for proteins interacting with FIH, the ARDs of p105 (NFKB1) and IB␣ were shown to be efficiently hydroxylated by FIH at specific Asn residues in the hairpin loops linking particular ankyrin repeats. The target Asn residue is highly conserved as part of the ankyrin consensus, and peptides derived from a diverse range of ARDcontaining proteins supported FIH enzyme activity. These findings demonstrate that this type of protein hydroxylation is not restricted to HIF and strongly suggest that FIH-dependent ARD hydroxylation is a common occurrence, potentially providing an oxygen-sensitive signal to a diverse range of processes.NF-B ͉ 2-oxoglutarate-dependent dioxygenase ͉ protein hydroxylation C ells react to variation in oxygen availability with adaptive responses that involve changes in most basic cellular functions. Analysis of the transcriptional component of this response has defined pathways that regulate hypoxia-inducible factor (HIF) by posttranslational hydroxylation of specific residues. HIF is an ␣͞␤ heterodimer that binds hypoxia response elements in a range of hypoxia-inducible genes (for review, see ref. 1). Regulation is mediated by the ␣-subunits and involves dual mechanisms controlling both the abundance and activity of the protein. Thus, hydroxylation of specific prolyl residues promotes interaction with the von Hippel-Lindau E3 ligase and hence proteolysis, whereas hydroxylation of a C-terminal Asn residue blocks recruitment of the coactivators p300͞CBP. The prolyl and asparaginyl hydroxylase enzymes that catalyze these reactions are 2-oxoglutarate (2-OG) and Fe(II)-dependent dioxygenases that couple the oxidative decarboxylation of 2-OG with oxidation of peptidyl substrates. Dioxygen is an obligate cosubstrate, and reductions in the rate of hydroxylation during hypoxia allow HIF-␣ to escape VHLmediated destruction and to activate transcription (for reviews, see refs. 2 and 3).HIF prolyl hydroxylation is catalyzed by three enzymes, PHD1, -2, and -3 (equivalent to EGLN2, -1, and -3 and HPH-3, -2, and -1). HIF Asn hydroxylation is catalyzed by a more distantly related 2-OG-dependent dioxygenase, factor inhibiting HIF (FIH) (for reviews, see refs. 2 and 3). A key question raised by these findings is whether the roles of all four dioxygenases are specific to HIF regulation, or whether one or more have alternative substrates. Several studies have identified proteins that interact to modulate HIF hydroxylase activity (4) or ...

Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor that directs a broad range of cellular responses to hypoxia. Recent studies have defined a set of 2-oxoglutarate and Fe(II)-dependent dioxygenases that modify HIF-␣ subunits by prolyl and asparaginyl hydroxylation. These processes potentially provide a dual system of control, down-regulating both HIF-␣ stability and transcriptional activity. Although genetic analyses in both primitive organisms and mammalian cells have demonstrated a critical role for the prolyl hydroxylase pathway in the regulation of HIF, analogous studies have not been performed on the HIF asparaginyl hydroxylase pathway, and its role in directing the expression of endogenous HIF transcriptional targets has not yet been clearly defined. Here we demonstrate, using small interfering RNA-mediated FIH suppression and controlled overexpression by a doxycycline-inducible system, that alterations in FIH expression in both directions have reciprocal effects on the expression of a range of HIF target genes. These effects were observed in normoxic and severely hypoxic cells but not anoxic cells. Evidence for FIH activity in severely hypoxic cells contrasted with results for the prolyl hydroxylase PHD2, suggesting that these enzymes display different oxygen dependence in vivo, with PHD2 requiring higher levels of oxygen for biological activity. Our results demonstrate an important physiological role for FIH in regulating HIF-dependent target genes over a wide range of oxygen tensions and indicate that inhibition of FIH has the potential to augment HIF target gene expression even in severe hypoxia.

Two human neuroblastoma (NB) cell lines, SH-SY5Y and Kelly, were found to express the gene for erythropoietin (EPO) in an oxygen (O 2 )-dependent manner. However, NB cells had maximal production of EPO with lower partial pressure of O 2 values than the well-characterized hepatoma cell line HepG2. This maximal EPO expression was preceded by accumulation of the O 2 -sensitive ␣ subunit of the heterodimeric transcription-factor complex hypoxia-inducible factor 1 (HIF-1). Western blot analysis revealed that the amount of the ␤ subunit of HIF-1, identical to aryl hydrocarbon receptor nuclear translocator 1 (ARNT1), and the homolog ARNT2 increased in nuclear extracts from SH-SY5Y cells exposed to anoxia. In neuronal cells, ARNT1 and ARNT2 can form a heterodimer with HIF-1␣, generating a functional HIF-1 complex. Using the hypoxia response element of the human EPO enhancer, we conducted electrophoretic mobility shift assays that showed accumulation and binding of HIF-1 complexes containing both ARNT1 and ARNT2 in NB cells. In addition to the HIF-1 complex, hepatocyte nuclear factor 4␣ (HNF4␣) was found to be indispensable for hypoxiainduced EPO gene expression in hepa- IntroductionHypoxia-inducible expression of the glycoprotein hormone erythropoietin (EPO) is part of the body's response to hypoxia, which includes up-regulation of oxygen (O 2 )-dependent genes involved in vascular tone and growth, metabolic adaptation, and O 2 delivery. 1,2 EPO is produced primarily by the kidneys and liver, but EPO gene expression has also been found in several other tissues, including brain tissue, 3 breast cancer cells, 4 female genital tract tissues, 5 and rat Sertoli cells. 6 EPO gene expression is regulated by the heterodimeric transcription-factor complex hypoxia-inducible factor 1 (HIF-1), which is composed of a 120-kDa O 2 -regulated ␣ subunit and a 91-to 94-kDa constitutively expressed ␤ subunit. 7 Under normoxic conditions, HIF-1␣ is posttranslationally hydroxylated at proline residues 402 and 564, 8 which tags the protein for ubiquitination by the E3 ubiquitin ligase complex containing the von Hippel-Lindau tumor-suppressor protein. 9,10 Subsequently, HIF-1␣ protein is rapidly degraded by the proteasome system. 11 Under hypoxic conditions, the ␣ subunit is stabilized because of the lack of proline hydroxylation and accumulates. Stabilized HIF-1␣ translocates into the nucleus and forms an HIF-1 complex with the almost ubiquitously expressed HIF-1␤ (identical to aryl hydrocarbon receptor nuclear translocator 1 [ARNT1]). The HIF-1 complex binds to hypoxia response elements (HREs) found in enhancers or promoters of hypoxia-inducible genes. 12 In addition to ARNT1, kidney and neuronal cells express the ARNT1 homolog ARNT2, which can form a functional HIF complex with HIF-1␣. 13 The HIF-1 binding site (HBS) in the 3Ј EPO enhancer is one of 3 sites that are important for hypoxia-induced EPO gene transcription. 14 The HBS is the most upstream element and is followed by a 4-base-pair (bp) CACA repeat and finally a direct repeat of ...

The von Hippel-Lindau tumor suppressor (pVHL) targets hydroxylated ␣-subunits of hypoxia-inducible factor (HIF) for ubiquitin-mediated proteasomal destruction through direct interaction with the hydroxyproline binding pocket in its ␤-domain. Although disruption of this process may contribute to VHL-associated tumor predisposition by up-regulation of HIF target genes, genetic and biochemical analyses support the existence of additional functions, including a role in the assembly of extracellular matrix. In an attempt to delineate these pathways, we searched for novel pVHL-binding proteins. Here we report a direct, hydroxylation-dependent interaction with ␣-chains of collagen IV. Interaction with pVHL was also observed with fibrillar collagen chains, but not the folded collagen triple helix. The interaction was suppressed by a wide range of tumor-associated mutations, including those that do not disturb the regulation of HIF, supporting a role in HIF-independent tumor suppressor functions.

No abstract

The glycoprotein hormone Erythropoietin (EPO) stimulates red cell production and maturation. EPO is produced by the kidneys and the fetal liver in response to hypoxia (HOX). Recently, EPO expression has also been observed in the central nervous system where it may be neuroprotective. It remained unclear, however, whether EPO is expressed in the peripheral nervous system and, if so, whether a neuronal phenotype is required for its regulation. Herein, we report that EPO expression was induced by HOX and a HOX mimetic in two cell lines derived from neuroblastoma (NB), a tumor of the peripheral nervous system. Both cell lines with inducible EPO expression, SH-SY5Y and Kelly cells, expressed typical neuronal markers like neuropeptide Y (NPY), growth-associated protein-43 (GAP-43), and neuron-specific enolase (ENO). NB cells with a more epithelial phenotype like SH-SHEP and LAN-5 did not show HOX inducible EPO gene regulation. Still, oxygen sensing and up-regulation of hypoxia-inducible factor-1 (HIF-1) were intact in all cell lines. We found that CpG methylation of the HIF binding site (HBS) in the EPO gene 3' enhancer was only present in the SH-SHEP and LAN-5 cells but not in SH-SY5Y and Kelly cells with regulated EPO expression. The addition of recombinant EPO to all NB cells, both under normoxic and hypoxic conditions, had no effect on cell proliferation. We conclude that the ability to respond to HOX with an increase in EPO expression in human NB may depend on CpG methylation and the differentiation status of these embryonic tumor cells but does not affect the proliferative characteristics of the cells.

Inhibition of the hypoxia-inducible factor (HIF) prolyl hydroxylases (PHD or EGLN enzymes) is of interest for the treatment of anemia and ischemia-related diseases. Most PHD inhibitors work by binding to the single ferrous ion and competing with 2-oxoglutarate (2OG) co-substrate for binding at the PHD active site. Non-specific iron chelators also inhibit the PHDs, both in vitro and in cells. We report the identification of dual action PHD inhibitors, which bind to the active site iron and also induce the binding of a second iron ion at the active site. Following analysis of small-molecule iron complexes and application of non-denaturing protein mass spectrometry to assess PHD2·iron·inhibitor stoichiometry, selected diacylhydrazines were identified as PHD2 inhibitors that induce the binding of a second iron ion. Some compounds were shown to inhibit the HIF hydroxylases in human hepatoma and renal carcinoma cell lines.